Search

Your search keyword '"Vanopdenbosch, Ludo"' showing total 173 results

Search Constraints

Start Over You searched for: Author "Vanopdenbosch, Ludo" Remove constraint Author: "Vanopdenbosch, Ludo"
173 results on '"Vanopdenbosch, Ludo"'

Search Results

3. Low Disease Activity Over 4 Years of Ocrelizumab Therapy in Treatment-naive Patients with High-activity, Early-stage Relapsing-remitting Multiple Sclerosis in the ENSEMBLE Study (P10-6.007)

5. A 36-Year-Old Man with Persistent Headache.

6. Multiple Sclerosis

10. Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting

11. Infusion-Related Reactions With Ocrelizumab: Risk Factors, Symptom Management and Patient Choices in the ENSEMBLE PLUS Study (P7-3.003)

12. Low Disease Activity Over 4 Years of Ocrelizumab Therapy in Treatment-Naive Patients With Early-Stage Relapsing-Remitting Multiple Sclerosis; the Phase IIIb ENSEMBLE Study (S46.004)

15. A Belgian consensus protocol for autologous hematopoietic stem cell transplantation in multiple sclerosis

17. The involvement of palliative care with neurology – a comparison of UK, Switzerland and Italy

18. The involvement of palliative care with neurology – a comparison of UK, Switzerland and Italy.

20. NEK1 genetic variability in a Belgian cohort of ALS and ALS-FTD patients

22. Safety and efficacy of natalizumab in Belgian multiple sclerosis patients: subgroup analysis of the natalizumab observational program

26. Recently Diagnosed Early-Stage RRMS: NEDA, ARR, Disability Progression, Serum Neurofilament and Safety: 1-Year Interim Data From the Ocrelizumab Phase IIIb ENSEMBLE Study (2261)

27. Efficacité d’ocrelizumab (OCR) dans l’étude de phase IIIb ENSEMBLE : résultats intermédiaires à 1 an sur le taux d’absence d’activité de la maladie (NEDA avec IRM de rebaseline) dans la sclérose en plaques récurrente-rémittente (SEP-RR) à un stade précoce

28. Quality indicators in neuro-oncology: Review of the literature and development of a new quality indicator set for glioma care through a two-round Delphi survey.

29. Assessment of Opicinumab in Acute Optic Neuritis Using Multifocal Visual Evoked Potential

30. Linezolid-induced inhibition of mitochondrial protein synthesis

37. Correction to: Management of immune thrombocytopenia in multiple sclerosis patients treated with alemtuzumab: a Belgian consensus (Acta Neurologica Belgica, (2018), 118, 1, (7-11), 10.1007/s13760-018-0882-3)

39. Fluoxetine in progressive multiple sclerosis: The FLUOX-PMS trial

42. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

43. Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting

44. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

45. NEK1 genetic variability in a Belgian cohort of ALS and ALS-FTD patients

47. Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial

48. Bing-Neel Syndrome: two unexpected cases and review of the literature

49. Predictors of response to opicinumab in acute optic neuritis.

50. Neuropalliative care in times of war.

Catalog

Books, media, physical & digital resources